Claims
- 1. A method of treating a condition or disease characterized by an excess of one or more androgens, said method comprising administering an effective amount of MIS to a patient.
- 2. The method of claim 1, wherein said one or more androgens is testosterone.
- 3. The method of claim 1, wherein said MIS has a molecular weight of about 140 kDa or about 70 kDa.
- 4. The method of claim 1, wherein said MIS is the C-terminal fragment of MIS.
- 5. The method of claim 3, wherein said C-terminal fragment has a molecular weight of about 25 kDa or about 12.5 kDa.
- 6. The method of claim 1, wherein said condition or disease is selected from the group consisting of polycystic ovarian disease and precocious puberty.
- 7. The method of claim 6, wherein said condition or disease is polycystic ovarian disease.
- 8. The method of claim 6, wherein said condition or disease is precocious puberty.
- 9. A method of treating a condition or disease characterized by an excess of one or more androgens, said method comprising administering an effective amount of a nucleic acid encoding MIS to a patient.
- 10. The method of claim 9, wherein said one or more androgens is testosterone.
- 11. The method of claim 9, wherein said MIS has a molecular weight of about 140 kDa or about 70 kDa.
- 12. The method of claim 9, wherein said MIS is the C-terminal fragment of MIS.
- 13. The method of claim 12, wherein said C-terminal fragment has a molecular weight of about 25 kDa or about 12.5 kDa.
- 14. The method of claim 9, wherein said condition or disease is selected from the group consisting of polycystic ovarian disease and precocious puberty.
- 15. The method of claim 14, wherein said condition or disease is polycystic ovarian disease.
- 16. The method of claim 14, wherein said condition or disease is precocious puberty.
- 17. A method of decreasing the plasma level of one or more androgens, said method comprising administering to a patient an effective amount of MIS, wherein said amount of MIS is sufficient to decrease the plasma level of said one or more androgens below the normal level for said one or more androgens.
- 18. The method of claim 17, wherein said one or more androgens is testosterone.
- 19. The method of claim 17, wherein said MIS has a molecular weight of about 140 kDa or about 70 kDa.
- 20. The method of claim 17, wherein said MIS is the C-terminal fragment of MIS.
- 21. The method of claim 20, wherein said C-terminal fragment has a molecular weight of about 25 kDa or about 12.5 kDa.
- 22. The method of claim 17, wherein said patient has benign prostatic hypertrophy, and wherein as a result of the administration of said MIS, the extent of said hypertrophy is diminished.
- 23. The method of claim 17, wherein said patient has prostate cancer, and wherein as a result of the administration of said MIS, the progression of said cancer is halted or slowed.
- 24. A method of decreasing the plasma level of one or more androgens, said method comprising administering to a patient an effective amount of nucleic acid encoding MIS, wherein said amount of MIS is sufficient to decrease the plasma level of said one or more androgens below the normal level for said one or more androgens.
- 25. The method of claim 24, wherein said one or more androgens is testosterone.
- 26. The method of claim 24, wherein said MIS has a molecular weight of about 140 kDa or about 70 kDa.
- 27. The method of claim 24, wherein said MIS is the C-terminal fragment of MIS.
- 28. The method of claim 27, wherein said C-terminal fragment has a molecular weight of about 25 kDa or about 12.5 kDa.
- 29. The method of claim 24, wherein said patient has benign prostatic hypertrophy, and wherein as a result of the administration of said nucleic acid, the extent of said hypertrophy is diminished.
- 30. The method of claim 24, wherein said patient has prostate cancer, and wherein as a result of the administration of said nucleic acid, the progression of said cancer is halted or slowed.
Parent Case Info
[0001] This application is a divisional of U.S. patent application Ser. No.09/662,341, filed Sep. 14, 2000, which claims priority benefit of U.S. provisional application No. 60/153,674, filed Sep. 14, 1999, and U.S. provisional application No. 60/153,940, filed Sep. 15, 1999, which are hereby incorporated by reference.
STATEMENTS AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY-SPONSORED RESEARCH AND DEVELOPEMENT
[0002] Part of the work performed during development of this invention utilized U.S. Government funds from National Cancer Institute grant no. R29CA79459, and from National Institute of Child Health and Human Development grant nos. RO1-HD-32112, P30-HD-28138, F32-HD-07954, and U54HD31398. The U.S. Government has certain rights in this invention.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60153674 |
Sep 1999 |
US |
|
60153940 |
Sep 1999 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09662341 |
Sep 2000 |
US |
Child |
10683346 |
Oct 2003 |
US |